Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer

Asian Journal of Andrology

Volumn 18, Issue 4, 2016, Pages 580-585

  Luo, Jun ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

androgen receptor; androgen receptor splice variant 7 (AR V7); castration resistance prostate cancer; circulating tumor cells; treatment selection

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR SPLICE VARIANT 7; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; ISOPROTEIN;

CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; HUMAN; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; DRUG RESISTANCE; GENETICS; MALE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR EMBOLISM;

DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN;

EID: 84977633717     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.178490     Document Type: Review

References (59)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 167: 948-51
2. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-42
3. Reiner WG, Scott WW, Eggleston JC, Walsh PC. Long term survival after hormonal therapy for stage D prostatic cancer. J Urol 1979; 122: 183-4
4. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, et al. Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: recommendations from the Prostate Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-7
5. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59
6. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16: 458-62
7. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8: 440-8
8. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15: 4792-8
9. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-48
10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
11. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371:1755-6
12. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97
13. Antonarakis ES, Eisenberger MA. Is abiraterone acetate well tolerated and effective in the treatment of castration resistant prostate cancer? Nat Clin Pract Oncol 2009; 6: 12-3
14. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8
15. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, et al. Significant and sustained antitumor activity in post docetaxel, castration resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-95
16. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, et al. Antitumour activity of MDV3100 in castration resistant prostate cancer: a phase 1 2 study. Lancet 2010; 375: 1437-46
17. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, et al. Development of a second generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90
18. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364: 2055-8
19. Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, et al. Improved survival in a cohort of trial participants with metastatic castration resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 2013; 64: 300-6
20. Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer 2014; 5: 265-73
21. Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med 2013; 368: 1458-9
22. Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration resistant prostate cancer: progresses and prospects. Oncogene 2014; 34: 1745-57
23. Ware KE, Garcia Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer 2014; 21: T87-103
24. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, et al. Distinct transcriptional programs mediated by the ligand dependent full length androgen receptor and its splice variants in castration resistant prostate cancer. Cancer Res 2012; 72: 3457-62
25. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, et al. Ligand independent androgen receptor variants derived from splicing of cryptic exons signify hormone refractory prostate cancer. Cancer Res 2009; 69: 16-22
26. Hu R, Isaacs WB, Luo J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 2011; 71: 1656-67
27. Lu C, Luo J. Decoding the androgen receptor splice variants. Transl Androl Urol 2013; 2: 178-86
28. Plymate SR, Luo J. The expression signature of androgen receptor splice variants and their distinctive transcriptional activities in castration resistant prostate cancer. In: Androgen Responsive Genes in Prostate Cancer. New York, USA: Springer; 2013. p. 201-13
29. Hu R, Denmeade SR, Luo J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab 2010; 5: 753-64
30. Jenster G, van der Korput JA, Trapman J, Brinkmann AO. Functional domains of the human androgen receptor. J Steroid Biochem Mol Biol 1992; 41: 671-5
31. Guo Z, Yang X, Sun F, Jiang R, Linn DE, et al. A novel androgen receptor splice variant is up regulated during prostate cancer progression and promotes androgen depletion resistant growth. Cancer Res 2009; 69: 2305-13
32. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration resistant prostate cancer cell lines. Cancer Res 2013; 73: 483-9
33. Chan SC, Selth LA, Li Y, Nyquist MD, Miao L, et al. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine based therapies. Nucleic Acids Res 2015; 43: 5880-97
34. Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res 2014; 20: 1590-600
35. Hornberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration resistance and short survival. PLoS One 2011; 6: e19059
36. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, et al. AR V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028-38
37. Antonarakis ES, Luo J. Prostate cancer: AR splice variant dimerization clinical implications. Nat Rev Urol 2015; 12: 431-3
38. Liang M, Adisetiyo H, Liu X, Liu R, Gill P, et al. Identification of androgen receptor splice variants in the pten deficient murine prostate cancer model. PLoS One 2015; 10: e0131232
39. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120: 2715-30
40. Xu D, Zhan Y, Qi Y, Cao B, Bai S, et al. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res 2015; 75: 3663-71
41. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, et al. Constitutively active androgen receptor splice variants expressed in castration resistant prostate cancer require full length androgen receptor. Proc Natl Acad Sci U S A 2010; 107: 16759-65
42. Yang L, Lin C, Jin C, Yang JC, Tanasa B, et al. lncRNA dependent mechanisms of androgen receptor regulated gene activation programs. Nature 2013; 500: 598-602
43. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62: 6606-14
44. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 2015; 163: 1011-25
45. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215-28
46. Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, et al. Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol 2016. Doi: 10.1016/j.eururo.2016.03.049. [Epub ahead of print]
47. Pan Q, Saltzman AL, Kim YK, Misquitta C, Shai O, et al. Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense mediated mRNA decay to control gene expression. Genes Dev 2006; 20: 153-8
48. Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One 2011; 6: e27970
49. Alix Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59: 110-8
50. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration resistant prostate cancer. JAMA Oncol 2015; 1: 582-91
51. Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, et al. Efficacy of cabazitaxel in castration resistant prostate cancer is independent of the presence of AR V7 in circulating tumor cells. Eur Urol 2015; 68: 939-45
52. Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, et al. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015; Doi: 10.18632/oncotarget.3925 [Epub ahead of print]
53. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, et al. Serial blood based analysis of AR V7 in men with advanced prostate cancer. Ann Oncol 2015; 26: 1859-65
54. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, et al. Systemic therapy in men with metastatic castration resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014; 32: 3436-48
55. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
56. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration resistant prostate cancer progressing after docetaxel treatment: a randomised open label trial. Lancet 2010; 376: 1147-54
57. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. Sipuleucel T immunotherapy for castration resistant prostate cancer. N Engl J Med 2010; 363: 411-22
58. Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, et al. Alpha emitter radium 223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-23
59. Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, et al. Biomarkers in the management and treatment of men with metastatic castration resistant prostate cancer. Eur Urol 2012; 61: 549-59